Valuation
Services-Medical LaboratoriesLive · Yahoo FinancePrice
$264.69
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — NTRA
Inflationary BoomStrengths
Gross Profit: $38.8M (+60.4% YoY) — Gross profit rose 60% — the spread between revenue and direct costs improved.
Operating Cash Flow: $215.3M (+58.7% YoY) — Operating cash flow grew 59% — the business generated more cash from day-to-day operations.
Total Assets: $2.4B (+44.4% YoY) — Total assets grew 44% — the company's resource base expanded.
Weaknesses
Net Income: -$208.2M (-9.3% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Revenue: $210.9M (-2.8% YoY) — Revenue fell 3% — the company generated less from its core operations.
R&D spending is 296% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $208.2M — the company spent more than it earned. Investors should monitor the path to profitability.
Financial Charts
Year-over-Year Changes
Gross Profit
$38.8M
was $24.2M
Gross profit rose 60% — the spread between revenue and direct costs improved.
Operating Cash Flow
$215.3M
was $135.7M
Operating cash flow grew 59% — the business generated more cash from day-to-day operations.
Total Assets
$2.4B
was $1.7B
Total assets grew 44% — the company's resource base expanded.
Net Income
-$208.2M
was -$190.4M
The company posted a net loss — total expenses exceeded total revenue.
Revenue
$210.9M
was $217.1M
Revenue fell 3% — the company generated less from its core operations.
Risk Flags
1 high · 0 medium · 1 low- ⚠ High
Net loss of $208.2M — the company spent more than it earned. Investors should monitor the path to profitability.
- ○ Low
R&D spending is 296% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade NTRA
Links open broker research pages. Not an endorsement or recommendation.
Research NATERA, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.